THE PERTHERA REPORT, PROVIDES PHYSICIANS WITH MORE
MEDICALLY AND SCIENTIFICALLY BASED THERAPEUTIC OPTIONS 

Physicians, in any setting – private practice, community hospital or major institution, can now provide their patients with therapeutic options previously unavailable to them.

Physicians no longer have to rely on nonspecific, one size fits all recommendations for their patients.  The oncology patient is no longer a “male in his 50’s whose biopsy reveals non–small-cell lung cancer” and offered a treatment that only about 10% of patients respond to, with a negligible survival benefit and significant side effects.

Perthera solves the complex problem of identifying, researching and recommending the precisely matched therapy to the patient.  As a result, Perthera leads oncologists to the best possible outcome for patients, extending patients’ lives and reducing the number of unsuccessful treatments leading to an improved quality of life for the patient and a reduction in cost.

This illustrates the fundamental idea behind personalized precision medicine: coupling established clinical–pathological indexes with state-of-the-art molecular profiling to create therapeutic strategies precisely tailored to each patient’s requirements.  Recent advances have led to an explosion of disease-relevant molecular information, with the potential for advancing patient treatment and care.

Perthera has met the challenges that precision medicine brings and has established frameworks for collecting, structuring, compiling, and interpreting the rapidly increasing volume of information and scientific developments.

Precision medicine is no longer a distant hope, with Perthera it’s living up to its promise.